Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Corticosteroids
6 evidence topics · 6 sources
Guideline recommendation for initial treatment
Certainty of randomized evidence for corticosteroids
“One non‐blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low‐quality evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate‐quality evidence), or change in disability or impairment after one year (low‐quality evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, corticosteroids are commonly used in practice, supported by very low‐quality evidence from observational studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pulsed dexamethasone versus daily prednisolone: remission at 12 months
“The primary outcome measure was remission at 12 months, defined as improvement of at least three points on the Rivermead mobility index and improvement of at least one point on the inflammatory neuropathy cause and treatment disability scale.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between December, 2003, and December, 2008, 40 patients were treated: 24 received dexamethasone and 16 received prednisolone. At 12 months, 16 patients were in remission: ten in the dexamethasone group and six in the prednisolone group (odds ratio [OR] 1.2, 95% CI 0.3-4.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most adverse events were minor and did not differ substantially between treatment groups; however, sleeplessness and Cushing's face occurred more often in the prednisolone group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term remission after corticosteroid courses
“Cure (>5 years off treatment) or remission according to the CDAS criteria after 1 or 2 courses of pulsed dexamethasone or daily prednisolone was achieved in 10 out of 39 patients (26%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the patients who were in remission after initial treatment experienced a relapse (median treatment-free interval: 17.5 months for dexamethasone, 11 months for prednisolone).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous methylprednisolone versus intravenous immunoglobulin over 6 months
“More patients stopped methylprednisolone (11 [52%] of 21) than IVIg (three [13%] of 24; relative risk 0·54, 95% CI 0·34-0·87; p=0·0085).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reasons for discontinuation were lack of efficacy (eight in the methylprednisolone group vs three in the IVIg group), adverse events (one in the methylprednisolone group), or voluntary withdrawal (two in the methylprednisolone group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After therapy discontinuation, more patients on IVIg worsened and required further therapy (eight [38%] of 21) than did those on methylprednisolone (none of ten; p=0·0317).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral prednisolone versus intravenous immunoglobulin: randomized crossover trial
“This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 mg daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-four of the thirty-two randomized patients completed both treatment periods.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was slightly, but not significantly, more improvement after IVIg than with prednisolone, the mean difference between the groups in change in disability grade being 0.16 (95% CI = -0.35 to 0.66).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A serious adverse event (psychosis) attributable to treatment occurred in one patient while on prednisolone and in none with IVIg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote